US EditionSemaglutide and Tirzepatide off FDA shortage list: What does this mean for weight loss drug access?
- The FDA approved Wegovy and Zepbound for weight loss, leading to increased discussion about GLP-1 drugs like semaglutide and tirzepatide, originally developed for diabetes management, and now widely debated in medicine and culture.
- Fueled by social media, off-label use of GLP-1 drugs has surged, with a Storyful Intelligence analysis of 29.9k mentions between February 1, 2024, and March 24, 2025, revealing discussions around conditions like PCOS and addiction.
- Some celebrities like Sharon Osbourne, who shed 42 pounds, and Whoopi Goldberg have openly discussed using weight loss injections like Ozempic and Mounjaro, while others like Gemma Collins claim these drugs have transformed their lives.
- Common side effects of GLP-1 drugs include nausea, especially when starting the medication, and more serious risks such as pancreatitis, while long-term effects remain unknown, and the new term 'Ozempic neck' refers to skin changes after using fat jabs.
- A clinical trial, STRIDE, showed that semaglutide, marketed as Ozempic and Wegovy, improved walking distance and quality of life for diabetes patients with peripheral artery disease, independent of weight loss, leading to calls for Health Canada and global guidelines to incorporate it into practice.
Insights by Ground AI
Does this summary seem wrong?
45 Articles
45 Articles
All
Left
4
Center
7
Right
4
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsSTRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
(MedPage Today) -- CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major...
·New York, United States
Read Full Article
The Gateway PunditReposted by 
DailyTruthReport
DailyTruthReportDr. McCullough Weighs In: The History & Future of GLP-1s
Dr. Peter McCullough examines the transformative journey of GLP-1 receptor agonists, highlighting the promising future of retatrutide. This post delves into innovative treatment options that could redefine weight management.
·United States
Read Full Article
Food vlogger Rocky Singh sheds 34 kg in a year, shuts down ‘use of Ozempic’ speculation with candid response
Rocky Singh also referenced a T-shirt from last year to highlight the difference in his weight and also addressed the ‘use of Ozempic’ speculation for his transformation
·New Delhi, India
Read Full ArticleCoverage Details
Total News Sources45
Leaning Left4Leaning Right4Center7Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 27%
C 47%
R 27%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
